TABLE 1.

Patient characteristics and transplantation procedure in patients with PTLD^a

Patient no.	Age (yr)	Disease	Donor	Immunosuppression	Day of engraftment	Antiviral treatment for prophylaxis or preemptive CMV therapy
1	26	SAA	MUD	ATG, CsA, MMF, prednisolone	17	days 0-30 ACV; from day 25, FC, GCV, GCV + FC
2	40	MDS	MFD	TGM, CsA	9	days 0-30 ACV; from day 30, GCV, GCV + FC
3	48	CML	2AgMM-FDb	None	14	days 0-30 ACV; from day 14, FC, GCV, GCV + FC
4	34	ALL	MUD	ATG, CsA, MMF, prednisolone	12	days 0-30 ACV; from day 52, FC, FC + GCV, cidofovir
5	24	ALL	MUD	ATG, CsA	11	days 0-30 ACV
6	31	ALL	MUD	ATG, CsA, MMF, prednisolone	11	days 0-30 ACV, from day 34, GCV, FC
7	34	AML	MUD	ATG, CsA, MMF, prednisolone	11	days 0-30 ACV
8	37	AML	1AgMM-DUb	ATG, CsA, OKT3	10c	days 0-30 ACV
9	54	MM	MUD	ATG, CsA, OKT3	28	days 0-30 ACV, from day 19, GCV

^aAbbreviations: SAA, severe aplastic anemia; MDS, myelodysplastic syndrome; CML, chronic myeloid leukemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; MM, multiple myeloma; MUD, matched unrelated donor; 2AgMM-FD, family donor with two antigen mismatches; 1AgMM-DU, unrelated donor with one antigen mismatch; ATG, antithymocyte globulin; CsA, cyclosporine; MMF, mycofenolate mofetil; ACV, acyclovir; FC, foscarnet; GCV, ganciclovir.

^bBoth patients received T-cell-depleted grafts.

^cPrimary graft failure with a second graft at day 34; engraftment was at day 10 after the second transplantation.